A new fund will pump more than $1 million into local organizations set to help those in need. Photo courtesy of Greater Houston Recovery Fund

Two Houston nonprofits have joined forces for the betterment of struggling Houstonians during the coronavirus pandemic.

As the jobless rate in America soars to 3.28 million and some 800,000 Texans slam the Texas Workforce Commission's lines, United Way of Greater Houston and the Greater Houston Community Foundation have teamed up to establish the Greater Houston COVID-19 Recovery Fund to help those in critical need. All money raised will be used to help with immediate basic needs, according to a press release.

The Houston Endowment is making a lead gift of $1 million to the fund and pledged an additional challenge gift of $1 million, which will match $1 for every $4 dollars raised. Additional leading Houston organizations who have pledged gifts to the fund include: JP Morgan Chase - $100,000; Houston Texans Foundation - $100,000, and Wells Fargo Foundation - $150,000.

"Nearly half of the households in our Greater Houston area struggle daily to make ends meet and the sudden loss of work, wages and child care can be a devastating financial hardship," says Anna M. Babin, president and CEO of United Way of Greater Houston. "Our primary goal is to make sure the most vulnerable in our community affected by COVID-19 have access to food, health care, shelter and other basic necessities to sustain them in this crisis."

These monies will be funneled to services provided by trusted nonprofit partners who have proven experience and the systems in place to serve the community in times of disaster; citizens in need can then approach said agencies directly, according to a spokesperson for the United Way.

For more assistance, Houstonians can call 2-1-1, which provides the most updated information on assistance with utilities, housing or rental assistance, crisis counseling, access to senior services, and information on food pantries in the community.

The recovery fund has been endorsed by Harris County Judge Lina Hidalgo and Houston Mayor Sylvester Turner. It is co-chaired by Jamey Rootes, board chair, United Way of Greater Houston and president of the Houston Texans; and by Tony Chase, board member, Greater Houston Community Foundation and chairman and CEO of ChaseSource, LP.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.